pharma · Psoriasis Vulgaris · Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.
LEO Pharma US
LEO Pharma A/S
LEO Pharma US clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Madison, USA
- Founded
- 1908
- Employees
- 75
- Programs
- 7
- Drugs
- 11
- Patents
- 0
LEO Pharma US projects
7 ClinicalTrials.gov programs sponsored by LEO Pharma US.
LEO Pharma US has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
LP0162-1336
LEO Pharma A/S
Treatment of moderate-to-severe Atopic dermatitis
1 trial -
Adtralza 150 mg solution for injection in pre-filled syringe
LEO Pharma A/S
Treatment of moderate-to-severe Atopic dermatitis
1 trial -
Delgocitinib cream, Cream Vehicle
LEO Pharma A/S
Mild to severe palmoplantar pustulosis
1 trial -
LEO 90105
LEO Pharma A/S
Psoriasis Vulgaris
1 trial -
LP0189-2318
LEO Pharma A/S
Gout flares
1 trial -
LP0160-1329
LEO Pharma A/S
Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.
1 trial -
LP0162-2328
LEO Pharma A/S
Atopic dermatitis and moderate-to severe atopic hand eczema
1 trial
Frequently asked questions
How many clinical projects does LEO Pharma US have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.